Guten Morgen

was sagt der Chart aus, kenne mich hier leider nicht aus.

1,130
         1§ 1.000
     1,125          §
         1§ 1
     0,950          §
         1§ 10.800
     0,620          §
         1§ 10.000
     0,450          §
         1§ 200
     0,200          §
         1§ 48.000
     0,178          §
         2§ 30.000
     0,175          §
         1§ 5.000
     0,160          §
         1§ 7.000
     0,140          §
         2§ 7.000

Und er bedeutet, dass am Anfang alles recht gut lief, bis ein einschneidendes Ereigniss den Kurs hat fallen lassen und nun dümplen wir seid Wochen hier unten rum

was soll das einschneidendes Ergebnis sein ?

Feb 06, 2012 72
        12§      Ebooks And Digital Documents Now Secured By Impervio
January 6th, 2012 55
        13§      Xelleon PLC 'Powers Up' with Goliath Promotions and Piershore Global for Music Service Launch
December 15th, 2011 90
        14§      Xelleon Moves Simpozia Server In Preparation for World Wide Lainch
November 4th, 2011 91
        15§      Xelleon Hires First US Sales
October 3rd, 2011 90
        16§      Direction Set, Focusing On Product Protection
September 22nd, 2011 114
        17§      Xelleon Hires IR Firm
September 16th, 2011 165
        18§      Xelleon Receives NATO Approval
August 3rd, 2011 123
        19§      Xelleon Final Negotiations On $1.2M Bulzi Contract
July 26th 2011 78
        20§      Xelleon Files With NATO
July 21, 2011 235
« START  PREV  1

wird Xell jetzt an der OTC gehandelt ?
Bei ariva wird der Börsenplatz angezeigt.

ich hoffe das geht hier nochmal gut.

jetzt auch an der OTC :-)

machen die Amis den Kurs :-)

"was soll das einschneidendes Ergebnis sein ?"

Ich weiß nicht welches Ereignis das war, zu der Zeit war ich noch nicht da. Ich dachte, ihr würdet wissen was da los war. Vielleicht hat jemand den Kurs manipuliert oder irgendjemand wusste seid dem mehr als wir. 

Das einschneidende Ereignis war der "EEG"-Hinweis:

www.wallstreet-online.de/diskussion/1172793-31-40/ 

kam eigentlich keine Meldung, dass Xell jetzt auch an der OTC handelbar ist.

Pink Sheets (OTC)
0,10 USD
+0,00+0,00%
19.04.17:38:47
29.000
    49.000§- USD
- Stk. - USD
- Stk.
- -

Xelleon PLC (XLL.F) CONCLUSION AND VALUATION

Xelleon's
encryption software solution Impervio(TM) as well as its Simpozia(TM) DRM
technology secures delivery of digital content over the web and
networks. The addressed market potential is tremendous. However, Xelleon
PLC (XLL.F) is still in the launching stage of its products and needs €
5 million capital in order to finance the market entry expenses.


Under the assumption of a successful market penetration, revenues for FY
2013 are expected to be around € 43.3 mn. accompanied by net earnings
of around € 18.3 mn.. In this context should be mentioned that on the
one hand the zero tax rate results from the fact, that the company is
registered on Isle of Man. On the other hand, the high profit margin
derives from the licensing sale strategy of the technology with low
material respectively fix costs arising.

Given our revenue and
profit forecast for the upcoming years, which is pretty much inline with
the company's guidance, the Discounted Cash Flow model delivers a fair
value of € 3.02. Taking the early stage of Xelleon PLC (XLL.F) (no track
record available) into consideration, we value the shares with a 50%
equity risk premium, which in our view reflects the risk connected to
that in an appropriate way.

With respect to the share price at the
time of the analysis (January 31, 2012, closing price XETRA) of € 0.91,
the price increase potential is 231.9%.

Therefore our investment recommendation is "UNDERVALUED".

Download the complete Report here: XLL.F Research 02-02-12

About CDC CAPITAL GMBH

"Trust Research" is a brand of CDC CAPITAL GMBH.

Conflicts of interest

CDC CAPITAL GMBH or its affiliates

1. do not own securities of the respective company

2. have not been involved in the issuance of securities of the respective company

3. have contractual relations with the respective company for providing investment research

The respective company is not participated in CDC CAPITAL GMBH.

Investment recommendations
UNDERVALUED: In our opinion, shares of the respective company should yield an increase in value of at least 15% over a twelve-month period.
FAIRLY VALUED:
In our opinion, shares of the respective company should yield a share
performance within a target corridor of +/- 15% over a twelve-month
period.
OVERVALUED: In our opinion, shares of the respective company will yield a decrease in value of at least 15% over a twelve-month period.

Information on the author and responsible parties

Author of this study: M. Schwarz, CDC CAPITAL GMBH

Responsible company: CDC CAPITAL GMBH, Freischützstr. 96, 81927 Munich

Additional information

Publication: Initial evaluation (Initial Coverage)

Date of first publication: February 1, 2012

Date of share price: January 31, 2012

Others: This study has been submitted to the company for review.

Supervisory authority

CDC CAPITAL GMBH is supervised by the Bundesanstalt für
Finanzdienstleistungsaufsicht (German Federal Financial Super-visory
Authority), Graurhein¬dorfer Straße 108, 53117 Bonn und Lurgiallee 12,
60439 Frankfurt.

DISCLAIMER

CDC CAPITAL GMBH
prepares its studies independent und is not impacted by the opinion of
the analysed company. The opin-ions and forecasts included in this
document are solely those of the analysts from CDC CAPITAL GMBH.
Information and opin-ions are date-related and can change at any time
due to internal or external events without prior notice as wells as
facts of the analysed company which were unknown at the time of the
analysis.

Studies prepared by CDC CAPITAL GMBH solely serve as
information and do not contain the basis for a contractual or other
obligation of any type.

CDC CAPITAL GMBH prepares its studies on the
basis of generally accessible sources which are believed to be
reliable, how-ever it has not independently assessed these sources.
Information received directly from the analysed company are - according
to generally accepted standards - used in good faith after plausibility
check. There is no guarantee that the information and data included in
these studies are balanced, precise, complete or correct. CDC CAPITAL
GMBH is not responsible or liable for any damages that result from the
use of these studies or the information contained therein. CDC CAPITAL
GMBH recommends that an investment decision should be based on other
sources like properly authorized prospectus and should not base on
studies from CDC CAPITAL GMBH.

In the United Kingdom, these studies
are only designated for distribution to authorized persons or
facultative persons according to the Financial Services Act 1986 or to
persons described in Art. 11 (3) of the Financial Services Act 1986
(Investments Adver-tisement) (Exemptions) Order 1996 (in the respective
applicable version) and may not be passed on to another group of
per-sons either directly or indirectly. Neither these studies nor any
copy thereof may be sent to, brought into, or distributed in the United
States of America or their respective territories or dependencies.


The compliance regulation from CDC CAPITAL GMBH conforms with the
requirements of the guideline regarding the concretion of the
organisational duties of financial service provider according to § 33
WpHG.

If you find our information valuable, Subscribe to Strategic Stocks and Penny Stocks RSS Feed by e-mail, to Receive our Updates INSTANTLY, and share this post/page with your friends and followers with use of the Social Buttons.

Like
all investment strategies, trading in stocks involves risk and
volatility. Past performance is not an indication of future results.
Actual results will be based on a consumer's individual purchase and
sale decisions.

Please read our Disclaimer regards to Xelleon PLC (XLL.F) or any company reviewed or blogged about at Strategic Penny Stocks.

Xelleon has just signed a contract with Equity Story to publish its AdHoc Updates, financial news and public reports.

The company's law firm has ordered the audit of Xelleon´s financials to be entered with Xelleon's Prospectus and is very confident that the German financial supervisory office BaFin will approve the Prospectus once it is completed and filed. Xelleon has also taken all necessary steps to facilitate its listing upgrade from First Quotation Board into the Entry Standard market segment on the Frankfurt Stock Exchange over the summer. The Firm has assured Xelleon there are no foreseeable problems with the application.

The company understands the listing requirements but haw no control over shareholder sentiment, automatic stop loss triggering or current market fear about first board companies.

Xelleon understands there have been hundreds of investors who have purchased Xelleon shares since the company was listed on the Frankfurt Stock Exchange in May 2011.

Company President Dale Scott Marion also stated "I personally believe that given the value of the Xelleon Assets and the company's strong fundamentals that the Xelleon share price does not properly reflect the company´s true value and there are professional reports available that confirm this assessment."

All in all Xelleon is seeing important progress on its products going to market and is on track with implementing its business plan and go-to-market strategy. Dale Marion said, “We are confident that the capital markets do appreciate successful companies and we expect this year 2012 to become very successful for Xelleon.”

Company Contact Information
Xelleon PLC
Dale Marion
12 Mount Havelock, Douglas, Isle Of Man.
M1 Y1R
+44 1622 37 0680

Press Release Distribution and Press Release Service by I-Newswire

Original Source: Xelleon PLC Issues Shareholder Assurance Letter

nicht gerade günstig


Frankfurt  20.000 0,06 €     0,80 €  50.000 1,23 T%  09:14:52